BridgeBio Pharma's banner

BridgeBio Pharma

@BridgeBioPharma • 2,034 subscribers

We move at the speed of patient need. We exist to bring meaningful medicines to people living with genetic conditions. $BBIO

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

AI can't compress a clinical trial. It can't generate the data we don't have yet. Our CEO Neil Kumar pushed back on the AI hype with @bloomberg at #MIGlobal with Milken Institute – not because the tools aren't valuable, but because the years still take years.

AI can't compress a clinical trial. It can't generate the data we don't have yet. Our CEO Neil Kumar pushed back on the AI hype with @bloomberg at #MIGlobal with Milken Institute – not because the tools aren't valuable, but because the years still take years.

BridgeBio Pharma

56,374 просмотров • 2 месяцев назад

Millions of people living with #geneticdiseases are still waiting for treatments. At BridgeBio, our mission is to put patients first and push the boundaries of science to meet those needs. CEO Neil Kumar Ph.D., joined Deirdre Bolton at the Milken Institute Global Conference to highlight the urgency and opportunity in addressing rare and underserved conditions. Listen to the full video here:

Millions of people living with #geneticdiseases are still waiting for treatments. At BridgeBio, our mission is to put patients first and push the boundaries of science to meet those needs. CEO Neil Kumar Ph.D., joined Deirdre Bolton at the Milken Institute Global Conference to highlight the urgency and opportunity in addressing rare and underserved conditions. Listen to the full video here:

BridgeBio Pharma

117,611 просмотров • 1 год назад

We are excited to announce that the U.S. FDA approved our orally-administered near-complete (≥90%) stabilizer of TTR for the treatment of adult patients with transthyretin cardiac amyloidosis (ATTR-CM). We are proud of the opportunity to serve patients within this community. Learn more:

We are excited to announce that the U.S. FDA approved our orally-administered near-complete (≥90%) stabilizer of TTR for the treatment of adult patients with transthyretin cardiac amyloidosis (ATTR-CM). We are proud of the opportunity to serve patients within this community. Learn more:

BridgeBio Pharma

43,642 просмотров • 1 год назад

Больше нет контента для загрузки